Omsav Pharma Research Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 25-06-2024
- Paid Up Capital ₹ 1.22 Cr
as on 25-06-2024
- Company Age 8 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.81 Cr
as on 25-06-2024
- Satisfied Charges ₹ 2.25 Cr
as on 25-06-2024
- Revenue -2.32%
(FY 2023)
- Profit 13.38%
(FY 2023)
- Ebitda 45.17%
(FY 2023)
- Net Worth 23.20%
(FY 2023)
- Total Assets 14.97%
(FY 2023)
About Omsav Pharma Research
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 1.22 Cr.
The company currently has active open charges totaling ₹7.81 Cr. The company has closed loans amounting to ₹2.25 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kewal Handa, Savita Tyagi, Rakhi Hiralal, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24230MH2016PTC339817
- Company No.
158537
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Feb 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Omsav Pharma Research?
Executive Team (1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Om Tyagi | Managing Director | 23-Feb-2016 | Current |
Board Members(6)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Ranchodlal Shah | Director | 07-Apr-2016 | Current |
Kewal Handa | Director | 24-Mar-2017 | Current |
Savita Tyagi | Director | 30-Sep-2022 | Current |
Rakhi Hiralal | Director | 07-Mar-2016 | Current |
Himadri Sen | Director | 12-Dec-2016 | Current |
Tushar Kumar | Director | 23-Feb-2016 | Current |
Financial Performance and Corporate Structure Insights of Omsav Pharma Research.
Omsav Pharma Research Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 2.32% decrease. The company also saw a substantial improvement in profitability, with a 13.38% increase in profit. The company's net worth Soared by an impressive increase of 23.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Omsav Pharma Research?
In 2023, Omsav Pharma Research had a promoter holding of 98.00% and a public holding of 2.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Conexus Social Responsibility Services Private Limited
Active 11 years 9 monthsKewal Handa is a mutual person
Charges (Loans)
Lender | Amount | Status |
---|---|---|
Bank Of India Creation Date: 25 Feb 2021 | ₹7.81 Cr | Open |
Yes Bank Limited Creation Date: 30 Aug 2018 | ₹2.25 Cr | Satisfied |
How Many Employees Work at Omsav Pharma Research?
Omsav Pharma Research has a workforce of 39 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Omsav Pharma Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Omsav Pharma Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.